Stockrabit · Analysts
Questions across 2 calls

Rajat Baldewa

Kizuna Wealth

Vijaya Diagnostic Centre Limited

Vijaya Diagnostic Centre Limited CC-May26.pdf · 2026-05-08
Yes. Hi, sir. Thank you for giving me the opportunity and congratulations on a good set of numbers. So, my first question would be like in Q4, the EBITDA margin came in 43.5%, which is 380 bps Y -o-Y expansion. But when you strip out the operating leverage on the fixed cost base, the other expense line grew 21% in Y -o-Y in Q4. So what specific cost levers drive this margin outperformance? Can you throw some color on that?
Okay. Great, sir. And sir, the last question on the revenue per test, which has been a jump by 4.3%. So even though your pathology, radiology mix is quite similar in FY'25. So is it because of wellness share increase or what's the reason?

Dr. Lal Path Labs Ltd.

Dr. Lal Path Labs Ltd. CC-May26.pdf · 2026-04-30
Hi sir, thank you for giving me the opportunity, my first question is on the acquisition side which you have acquired Shahbazkers Diagnostic Centre for upto Rs. 20 crore, about 3.3x FY26 revenue of Rs. 6.11 crore. Given that Mumbai's crowded lab market, like Metropolis, ID Lab s, and there are many phenomenon labs , w hat was the competitive intensity there? And is this a mainly 2 holed acquisition or the first of multiple bolt-ons in Maharashtra?
Great sir, and sir, is there any plan on radiology side given that 3-4 year growth plan particularly on radiology?